Castle Biosciences (CSTL) risk factors, FY2025 10-K

Risks Related to Our Financial Condition

1. 01A significant portion of our revenue comes from a small number of third-party payors34% rewritten
2. 02Due to how we recognize revenue, our quarterly and annual revenues may not reflect our underlying business
3. 03We incurred significant losses in the past, and we may be unable to achieve sustained profitability in the future41% rewritten
4. 04Changes in financial accounting standards or practices may cause adverse, unexpected financial reporting fluctuations and affect our reported operating results
5. 05Our quarterly and annual operating results and cash flows may fluctuate in the future, which could cause the market price of our stock to decline substantially
6. 06We may need to raise additional capital to fund our existing operations, commercialize new products or expand our operations29% rewritten
7. 07The terms of the 2024 LSA place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our operating and financial flexibility25% rewritten

Risks Related to Our Business

1. 08Our revenue currently depends primarily on sales from our DecisionDx-Melanoma, TissueCypher and DecisionDx-SCC tests, and we will need to generate sufficient revenue from these products and other products to grow our business49% rewritten
2. 09Unfavorable U.S. and global economic conditions could adversely affect our business, financial condition, results of operations or cash flows34% rewritten
3. 10Billing for our products is complex and requires substantial time and resources to collect payment
4. 11As we introduce new products, we may need to add new codes to our billing process as well as our financial reporting systems. Failure or delays in effecting these changes in external billing and internal systems and processes could negatively affect our collection rates, revenue and cost of collecting
5. 12We rely on our database of samples for some of the development and improvement of our products. Depletion or loss of our samples could significantly harm our business
6. 13If one or more of our primary clinical laboratory facilities become damaged or inoperable or we are required to vacate our existing facilities, our ability to conduct our laboratory analysis and pursue our R&D efforts may be jeopardized
7. 14Our current or future products may not achieve or maintain significant commercial market acceptance
8. 15New product development involves a lengthy and complex process, and we may be unable to develop and commercialize, or receive reimbursement for, on a timely basis, or at all, new products36% rewritten
9. 16We may experience limits on our revenue if we are unable to increase and support adoption of our products by physicians and other healthcare providers34% rewritten
10. 17We rely on limited or sole suppliers for some of the reagents, equipment, chips and other materials used by our products, and we may not be able to find replacements or transition to alternative suppliers
11. 18If our products do not meet the expectations of clinicians and patients, our operating results, reputation and business could suffer
12. 19In addition, competitors may develop their own versions of our solutions in countries where we do not have patents or where our intellectual property rights are not recognized and compete with us in those countries, including encouraging the use of their solutions by clinicians in other countries
13. 20Impairment of our goodwill or other intangible assets could have a material adverse effect on our operating results and financial condition
14. 21The sizes of the TAM for our current and future products have not been established with precision and may be smaller than we estimate
15. 22The diagnostic testing industry is subject to rapid change, which could make our current or future products obsolete
16. 23Our business operations may subject us to disputes, claims, government investigations and lawsuits, which may be costly and time-consuming and could materially and adversely impact our financial position and results of operations

Risks Related to Reimbursement and Government Regulation

1. 24We generally have limited reimbursement coverage for our products, and if third-party payors, including government and commercial payors, do not provide sufficient coverage of, or adequate reimbursement for, our products, our commercial success, including revenue, will be negatively affected69% rewritten
2. 25If we are unable to obtain and maintain adequate reimbursement rates from commercial third-party payors, this may adversely affect our Medicare rate. It is unclear what impact new pricing structures, such as those adopted under PAMA, may have on our business, financial condition, results of operations or cash flows
3. 26We expect to continue to focus substantial resources on increasing coverage and reimbursement for our current products and any future products we may develop. We believe it may take several years to achieve broad coverage and adequate contracted reimbursement with a majority of third-party payors for our products
4. 27Our products are currently marketed as LDTs, and any changes in regulations or the FDA’s enforcement discretion for LDTs, or violations of regulations by us, could adversely affect our business, prospects, results of operations or financial condition77% rewritten
5. 28In addition, Congress has, for over the past decade, considered a number of proposals, which, if enacted, would subject LDTs to additional regulatory requirements. Any such legislation could substantially alter our marketing of LDTs and negatively impact our business, financial condition, and results of operationsNew
6. 29All of our laboratories undergo CAP accreditation to maintain CLIA certification. The most recent CAP inspections for the Phoenix and Pittsburgh laboratories occurred in October 2024
7. 30Doing business with the public sector, including the U.S. government, subjects us to risk of audits, investigations, sanctions and penalties28% rewritten
8. 31Failure to timely obtain necessary marketing authorizations for our products that are intended for clinical or diagnostic uses may have a material adverse effect on our business, financial condition, results of operations, and prospectsNew
9. 32New legislation or regulation in the U.S. may make it more difficult and costly for us to manufacture, market, or distribute our products, or to obtain marketing authorizations for any future productsNew
10. 33Disruptions at the FDA and other government agencies caused by layoffs, funding shortages or global health concerns could negatively impact our businessNew
11. 34We cannot predict the likelihood, nature or extent of government regulation or other measures that may arise from future legislation or administrative or executive action, either in the U.S. or abroadNew
12. 35Interim, topline and preliminary data from our clinical studies that we announce or publish from time to time may change as more data becomes available and are subject to audit and verification procedures that could result in material changes in the final data
13. 36In March 2010, the ACA became law. This law substantially changed the way healthcare is financed by both government and commercial third-party payors, and significantly impacted our industry
14. 37Ethical, legal and social concerns related to the use of genetic information could reduce demand for our products
15. 38Evolving expectations around corporate responsibility practices, specifically related to environmental, social and governance (“ESG”) matters, may expose us to reputational and other risks

Risks Related to Intellectual Property

1. 39We may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the rights to patents licensed from or to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business
2. 40Changes in patent law in the U.S. and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products
3. 41The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations
4. 42Issued patents covering our products and related technologies could be found invalid or unenforceable if challenged
5. 43Our commercial success depends significantly on our ability to operate without infringing upon the intellectual property rights of third parties
6. 44We depend on information technology systems that we license from third parties. Any failure of such systems or loss of licenses to the software that comprises an essential element of such systems could significantly harm our business
7. 45In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations
8. 46We may not be able to protect our intellectual property rights throughout the world
9. 47If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our business could be harmed
10. 48We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties
11. 49If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
12. 50We may be subject to claims challenging the inventorship of our patents and other intellectual property
13. 51Obtaining and maintaining our patent protection depends on compliance with various required procedures, document submissions, fee payments and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
14. 52Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time

Risks Related to Employee Matters and Managing Growth and Other Risks Related to Our Business

1. 53We are highly dependent on the services of our key personnel, including our President and Chief Executive Officer
2. 54Our employees, clinical investigators, consultants, speakers, vendors and any current or potential commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading
3. 55We may be unable to manage our future growth effectively, which could make it difficult to execute our business strategy
4. 56Our ability to use net operating loss carryforwards and certain other tax attributes to offset future taxable income and taxes may be subject to limitations25% rewritten
5. 57Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations66% rewritten
6. 58In the ordinary course of business, we and the third parties with whom we work (such as contractors and consultants) process proprietary, confidential and sensitive information (including but not limited to intellectual property, proprietary business information and personal data)
7. 59Remote work poses risks to our information technology systems and data, as our employees utilize network connections, computers and devices outside our premises or network, including working at home, while in transit and in public locations55% rewritten
8. 60In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive information about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position
9. 61Product or professional liability lawsuits against us could cause us to incur substantial liabilities and could limit our commercialization of our products
10. 62International expansion of our business exposes us to business, regulatory, political, operational, financial, and economic risks associated with doing business outside of the U.S
11. 63Requirements associated with being a public company, including those related to our status as an accelerated filer and no longer qualifying as a smaller reporting company, have increased our costs and diverted significant company resources and management attention
12. 64If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
13. 65Our business could be adversely impacted by inflation
14. 66Our business could be adversely affected by natural disasters, public health crises and other events beyond our control

Risks Related to Ownership of Our Common Stock

1. 67The price of our common stock may be volatile or may decline regardless of our operating performance, and you may lose all or part of your investment
2. 68If there are substantial sales of shares of our common stock, the price of our common stock could decline
3. 69We have broad discretion in the use of working capital and may not use it effectively or in ways that increase our share price
4. 70If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline
5. 71Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
6. 72We have and may continue to enter into related party transactions that create conflicts of interest, or the appearance of conflicts of interest, which may harm our business and cause our stock price to decline
7. 73We do not intend to pay dividends for the foreseeable future
8. 74The concentration of our stock ownership will likely limit your ability to influence corporate matters, including the ability to influence the outcome of director elections and other matters requiring stockholder approval
9. 75Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock
10. 76The amendment of any of these provisions, with the exception of the ability of our board of directors to issue shares of preferred stock and designate any rights, preferences and privileges thereto, would require approval by the holders of at least 66-2/3% of our then-outstanding common stock